Free Trial

Cytek Biosciences (CTKB) News Today

Cytek Biosciences logo
$2.42 -0.03 (-1.02%)
As of 10:21 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CTKB Latest News

Cytek Biosciences, Inc. stock logo
Point72 Asset Management L.P. Makes New Investment in Cytek Biosciences, Inc. (NASDAQ:CTKB)
Point72 Asset Management L.P. bought a new position in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 389,359 shares of the c
Cytek Biosciences, Inc. stock logo
BNP Paribas Financial Markets Takes Position in Cytek Biosciences, Inc. (NASDAQ:CTKB)
BNP Paribas Financial Markets bought a new position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 208,664 shares of the company's stock, v
Cytek Biosciences, Inc. stock logo
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stake Raised by Northern Trust Corp
Northern Trust Corp boosted its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 11.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,188,331 shares of the company's st
Cytek Biosciences, Inc. stock logo
Cubist Systematic Strategies LLC Purchases Shares of 116,624 Cytek Biosciences, Inc. (NASDAQ:CTKB)
Cubist Systematic Strategies LLC bought a new position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 116,624 shares of the
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (NASDAQ:CTKB) Price Target Lowered to $3.00 at The Goldman Sachs Group
The Goldman Sachs Group cut their price target on Cytek Biosciences from $3.50 to $3.00 and set a "sell" rating for the company in a research note on Monday.
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (NASDAQ:CTKB) Releases Earnings Results, Misses Expectations By $0.05 EPS
Cytek Biosciences (NASDAQ:CTKB - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.05). Cytek Biosciences had a negative return on equity of 2.58% and a negative net margin of 5.05%.
Cytek Biosciences, Inc. stock logo
Dimensional Fund Advisors LP Grows Position in Cytek Biosciences, Inc. (NASDAQ:CTKB)
Dimensional Fund Advisors LP lifted its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 16.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,830,432 shares of the compan
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (NASDAQ:CTKB) Stock Rating Lowered by TD Cowen
TD Cowen lowered shares of Cytek Biosciences from a "buy" rating to a "hold" rating and set a $4.00 price objective on the stock. in a research report on Friday.
Cytek Biosciences, Inc. stock logo
Raymond James Financial Inc. Invests $765,000 in Cytek Biosciences, Inc. (NASDAQ:CTKB)
Raymond James Financial Inc. purchased a new stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 117,870 shares of the company's stock, valued at appro
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (CTKB) Projected to Post Quarterly Earnings on Thursday
Cytek Biosciences (NASDAQ:CTKB) will be releasing its Q1 2025 earnings after the market closes on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-cytek-biosciences-inc-stock/)
Cytek Biosciences, Inc. stock logo
Topline Capital Management LLC Acquires New Position in Cytek Biosciences, Inc. (NASDAQ:CTKB)
Topline Capital Management LLC bought a new position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 236,596 shares of the company's stock, val
Cytek Biosciences, Inc. stock logo
Renaissance Technologies LLC Purchases 251,000 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)
Renaissance Technologies LLC grew its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 118.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 462,600 shares of the company's stock after purchasing an additional 251,000 sh
Cytek Biosciences, Inc. stock logo
Cytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Update
Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 4,530,000 shares, a growth of 18.9% from the March 15th total of 3,810,000 shares. Currently, 3.9% of the shares of the stock are sold short. Based on an average daily volume of 878,800 shares, the days-to-cover ratio is currently 5.2 days.
Cytek Biosciences, Inc. stock logo
JPMorgan Chase & Co. Raises Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)
JPMorgan Chase & Co. increased its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 58.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 947,683 shares of the company's stock after buying a
Cytek Biosciences, Inc. stock logo
Trexquant Investment LP Has $1.57 Million Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)
Trexquant Investment LP boosted its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 50.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 242,599 shares of the company's
Cytek Biosciences, Inc. stock logo
Wellington Management Group LLP Decreases Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB)
Wellington Management Group LLP lowered its stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 24.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,517,214 shar
Cytek Biosciences, Inc. stock logo
Raymond James Financial Inc. Buys New Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)
Raymond James Financial Inc. purchased a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 117,870 shares of the company's stock, valued at approxi
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (NASDAQ:CTKB) Hits New 52-Week Low - Here's Why
Cytek Biosciences (NASDAQ:CTKB) Sets New 12-Month Low - Here's What Happened
Cytek Biosciences, Inc. stock logo
106,597 Shares in Cytek Biosciences, Inc. (NASDAQ:CTKB) Purchased by Teacher Retirement System of Texas
Teacher Retirement System of Texas bought a new position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 106,597 shares of the company's stock, valued at approximately $6
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (NASDAQ:CTKB) Sets New 12-Month Low - Should You Sell?
Cytek Biosciences (NASDAQ:CTKB) Hits New 1-Year Low - Time to Sell?
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (NASDAQ:CTKB) Trading Up 2.2% - Time to Buy?
Cytek Biosciences (NASDAQ:CTKB) Trading 2.2% Higher - Time to Buy?
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (NASDAQ:CTKB) Hits New 12-Month Low - Should You Sell?
Cytek Biosciences (NASDAQ:CTKB) Sets New 1-Year Low - What's Next?
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (NASDAQ:CTKB) Receives "Overweight" Rating from Stephens
Stephens reiterated an "overweight" rating and issued a $6.00 price target on shares of Cytek Biosciences in a research note on Wednesday.
Cytek Biosciences, Inc. stock logo
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Purchased by Royce & Associates LP
Royce & Associates LP lifted its position in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 159.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 470,819 shares of the company's stock after acquiring
Cytek Biosciences, Inc. stock logo
Globeflex Capital L P Purchases Shares of 84,434 Cytek Biosciences, Inc. (NASDAQ:CTKB)
Globeflex Capital L P purchased a new stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 84,434 shares of the company's stock, valued
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (NASDAQ:CTKB) Sets New 1-Year Low - Here's What Happened
Cytek Biosciences (NASDAQ:CTKB) Hits New 1-Year Low - Should You Sell?
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Here's What Happened
Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Here's Why
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (NASDAQ:CTKB) Price Target Lowered to $8.00 at Piper Sandler
Piper Sandler decreased their target price on Cytek Biosciences from $8.50 to $8.00 and set an "overweight" rating for the company in a research note on Tuesday.
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (CTKB) Expected to Announce Quarterly Earnings on Wednesday
Cytek Biosciences (NASDAQ:CTKB) will be releasing earnings after the market closes on Wednesday, March 12. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=666441)
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (NASDAQ:CTKB) Sets New 52-Week Low - Should You Sell?
Cytek Biosciences (NASDAQ:CTKB) Hits New 52-Week Low - What's Next?
Cytek Biosciences, Inc. stock logo
Cytek Biosciences (NASDAQ:CTKB) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Cytek Biosciences (NASDAQ:CTKB - Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of $0.05 by $0.02. Cytek Biosciences had a negative return on equity of 2.58% and a negative net margin of 5.05%.
Cytek Biosciences sees FY25 revenue $204M-$212M, consensus $216.52M
Cytek Biosciences reports Q4 revenue $57.48M, consensus $59.38M
Cytek Biosciences, Inc. stock logo
Cytek Biosciences, Inc. (NASDAQ:CTKB) Sees Significant Decline in Short Interest
Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 3,170,000 shares, a decrease of 8.6% from the January 15th total of 3,470,000 shares. Approximately 2.7% of the shares of the stock are short sold. Based on an average daily volume of 799,100 shares, the days-to-cover ratio is presently 4.0 days.
Get Cytek Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter.

CTKB Media Mentions By Week

CTKB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CTKB
News Sentiment

1.29

0.69

Average
Medical
News Sentiment

CTKB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CTKB Articles
This Week

4

2

CTKB Articles
Average Week

Get Cytek Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CTKB) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners